CTKB - CIK 0001831915
The table below shows Cytek Biosciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $65.67M | $93.28M | $75.47M | $95.30M | $162.27M | $177.89M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $51.90M | $56.63M | $56.23M | $55.03M | $52.63M | $44.64M |
| Inventory | $49.79M | $51.65M | $49.49M | $45.35M | $46.80M | $50.07M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $379.30M |
| $388.49M |
| $382.82M |
| $380.50M |
| $390.19M |
| $384.08M |
| Property, plant & equipment | $20.47M | $18.05M | $18.35M | $17.83M | $18.51M | $18.11M |
| Goodwill | $16.69M | $16.70M | $16.71M | $16.68M | $16.18M | $16.18M |
| Total assets | $449.11M | $494.92M | $493.32M | $482.60M | $491.23M | $483.73M |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $80.94M | $75.21M | $73.27M | $67.69M | $62.80M | $52.38M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $121.47M | $116.35M | $115.76M | $102.97M | $105.76M | $94.60M |
| Retained earnings | -$120.60M | -$57.66M | -$52.18M | -$46.60M | -$44.84M | -$45.78M |
| Total equity | $327.64M | $378.57M | $377.56M | $379.62M | $385.46M | $389.12M |